Seasonal influenza vaccine effectiveness estimates: Development of a parsimonious case test negative model using a causal approach

Vaccine
Courtney R LaneH A Kelly

Abstract

Influenza vaccine effectiveness (VE) is increasingly estimated using the case-test negative study design. Cases have a symptom complex consistent with influenza and test positive for influenza, while non-cases have the same symptom complex but test negative. We aimed to determine a parsimonious logistic regression model for this study design when applied to patients in the community. To determine the minimum covariate set required, we used a previously published systematic review to find covariates and restriction criteria commonly included in case-test negative logistic regression models. Covariates were assessed for inclusion using a directed acyclic graph. We used data from the Victorian Influenza Sentinel Practice Network from 2007 to 2013, excluding the pandemic year of 2009, to test the model. VE was estimated as (1-adjusted OR) * 100%. Changes in model fit from addition of specified covariates were examined. Restriction criteria were examined using change in VE estimate. VE was estimated for each year, all years aggregated, and for influenza type and sub-type. Using publicly available software, the directed acyclic graph indicated that covariates specifying age, time within the influenza season, immunocompromising comorb...Continue Reading

References

Jun 28, 2003·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·Karin ThurskyHeath Kelly
Apr 4, 2007·International Journal of Epidemiology·Evan W OrensteinWalter A Orenstein
Dec 18, 2008·The Journal of Infectious Diseases·Edward A BelongiaUNKNOWN Marshfield Influenza Study Group
Jul 19, 2011·Emerging Infectious Diseases·James E FieldingHeath A Kelly
Apr 28, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Danuta M SkowronskiMartin Petric
Jul 31, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·John J TreanorUNKNOWN US Flu-VE Network
Jan 18, 2013·MMWR. Morbidity and Mortality Weekly Report·UNKNOWN Centers for Disease Control and Prevention (CDC)
Feb 5, 2013·South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde·B D Schoub
Mar 19, 2013·Vaccine·Michael L Jackson, Jennifer C Nelson
Apr 27, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sheena G Sullivan, Heath Kelly
Oct 2, 2013·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·G De SerresC S Ambrose
Nov 16, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Suzanne E OhmitArnold S Monto
Oct 2, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Huong Q McLeanEdward A Belongia
Oct 29, 2014·Expert Review of Vaccines·Sheena G SullivanBenjamin J Cowling
Oct 31, 2014·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·N TurnerUNKNOWN SHIVERS investigation team
Nov 13, 2014·The Medical Journal of Australia·Heath A Kelly

❮ Previous
Next ❯

Citations

Apr 25, 2019·Medical Teacher·Mark R Raymond, Joseph P Grande
May 16, 2019·Communicable Diseases Intelligence·Olivia PriceSheena Sullivan
Jan 29, 2021·International Journal of Environmental Research and Public Health·Antonio CarmonaJavier Díez-Domingo

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.